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1. Introduction 
Hematopoietic stem cells (HSCs) are multipotent stem cells defined by their ability to self-
renewal, differentiation and maintenance of all blood cell types in the hematological system 
during the entire lifetime of the organism. This physiological process, called hematopoiesis, 
is controlled by several complex interactions between genetic processes in blood progenitor 
cells and bone marrow microenvironment. Hemostasis is maintained by a delicate balance 
between processes such as self-renewal, proliferation and differentiation versus apoptosis 
and cell-cycle arrest in HSCs. Over the last two decades, several studies have been made to 
understand possible mechanisms of cell malignancy and tumor growth, both in solid and 
hematological cancers. Leukemias are hematological malignancies that arise from cancer 
stem cells (CSCs). Neoplastic transformation of hematopoietic stem or progenitor cells 
occurs by unbalanced critical mechanisms. Blood cancers, as acute myeloid leukemia 
(AML), are sustained by leukemic stem cells (LSCs) which, like normal HSCs, present a 
range of biological characteristics that enable their long-term survival. AML is a well 
studied hematological cancer type characterized by an accumulation of clonal myeloid 
progenitor cells that do not differentiate normally. However, there is still no consensus 
about the mechanisms by which the HSCs transformation occurs. In this chapter, the 
hematopoietic stem cells and leukemic stem cells will be focused on leukemia development, 
mainly in AML. 
2. Hematopoietic stem cells 
Hematopoietic stem cells are a well characterized stem cell type which has been used in 
bone marrow transplantation for treatment of hematological malignancies as well as non-
malignant disorders (Warner et al, 2004). In fact, bone marrow (BM) has been, for many 
years, transplanted as an unfractionated cell pool, until researchers discovered which 
cellular components were responsible for the engraftment of the donor hematopoietic and 
immune systems in marrow-ablated patients.  
HSCs present self-renewal potential and differentiation capacity into blood lineages. The 
self-renewal concept means that when stem cells divide, 50% of the daughter cells, on 
average, is committed with a cell lineage; the remaining 50% do not differentiate; therefore 
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the process maintains the same number of stem cells. This is accomplished by the so-called 
asymmetric cell division, so that each dividing stem cell originates one new stem cell and 
one differentiated cell (Gordon, 2005) (Figure 1). In the symmetric division, the stem cells 
originate 100% of identical stem cells. 
 
Fig. 1. Schematic illustration of two different types of HSCs division. On the left, the 
symmetric division in which mitosis originates two identical stem cell daughters. On the 
right, the characteristic stem cells asymmetric division where each dividing stem cell forms 
one new stem cell and one differentiated cell. 
HSCs are classified as multipotent stem cells due to their ability to differentiate in lymphoid 
as well as myeloid cells types; however, some studies showed that transplanted bone 
marrow cells can contribute to the repair and regeneration of a spectrum of other tissue cell 
types including those from brain, muscle, lung and liver. 
Lymphoid cell lineage includes T and B cells, while megakaryocytes, erythrocytes, 
granulocytes and macrophages belong to the myeloid lineage. These two lineages derive 
from different progenitor cells. Common lymphoid progenitors (CLPs) can differentiate into 
all types of lymphocytes without noticeable myeloid potential under physiological 
conditions. Similarly, common myeloid progenitors (CMPs) can give rise to all classes of 
myeloid cells with no or extensively low levels of B-cell potential (Kondo, 2010). It is likely 
that differences in the expression levels of transcription factors determine the lineage 
affiliation of a differentiating cell (Figure 2). The transcription factors PU.1 and GATA-1 
have been implicated in myeloid and erythroid/megakaryocyte lineage differentiation, 
respectively (Gordon, 2005). 
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Fig. 2. HSCs differentiation pathways. HSCs could differentiate into specific lymphoid and 
myeloid cell types. Common lymphoid progenitors (CLPs) can differentiate into all types of 
lymphocytes and common myeloid progenitors (CMPs) can give rise to all classes of 
myeloid cells (megakaryocytes, erythrocytes, granulocytes and macrophages) (Adapted 
from Du et al., 2008). 
2.1 Characterization 
Morphologically, hematopoietic stem cells are undifferentiated and resemble small 
lymphocytes. Normally, a large fraction is quiescent, in the G0 phase of the cell cycle, which 
protects them from the action of cell cycle-dependent drugs. The quiescent state of stem cells 
is maintained by transforming growth factor-ǃ (TGF-ǃ). The activity of TGF-ǃ is mediated 
by p53, a tumor suppressor gene that regulates cell proliferation and targets the cyclin-
dependent kinase inhibitor p21 (Gordon, 2005). Quiescence of HSCs is critical not only for 
protecting the stem cell compartment and sustaining stem cell pools during long periods of 
time, but also by minimizing the accumulation of replication-associated mutations. 
Quiescence regulation in HSCs is also of great importance for understanding the 
pathophysiological origins of many related disorders. Interestingly, many of the intrinsic 
transcriptional factors that maintain HSCs quiescence are found to be associated with 
leukemias. For example, chromosomal translocations resulting in the fusion of FoxOs and 
myeloid/lymphoid or mixed lineage leukemia have been reported in acute myeloid leukemias. 
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The majority of normal HSCs are present among the CD34+/CD38− bone marrow cell 
fractions; some HSCs are also observed among CD34−/Lin− cells; CD34+/CD38+ cell 
fractions contain some HSCs but endowed with short-term repopulating activity. Other 
recognized marker is the tyrosine kinase receptor c-kit (CD117), concomitantly with the lack 
of terminal differentiation markers (as CD4 and CD8; Figure 3) (Rossi et al., 2011).  
Primitive HSCs populations show low fluorescence ratios after Hoechst 33342 and 
Rhodamine 123 staining; these cells are described as side population (SP). SP cells 
demonstrate high expression of ATP binding cassette (ABC) transporters as P-glycoprotein 
(P-gp/ABCB1), breast cancer resistance protein (BCRP/ABCG2) and lung resistance protein 
(LRP) (Huls et al., 2009). MDR1 has been implicated in the protection of cells against 
apoptotic cell death induced by a variety of methods including growth factor deprivation, 
UV irradiation, ionizing radiation, or tumor necrosis factor-ǂ treatment. BCRP is a half-
transporter and characterized as a novel stem cell transporter. Like MDR1, enforced 
overexpression of BCRP in human MCF-7 breast cancer cells confers a broad spectrum of 
drug resistance, and elevated levels of expression of BCRP have been reported to be 
associated with acute myeloid leukemia.   
Since ABC transporter function is associated with both normal and aberrant hematopoiesis, 
it is important to fully characterize the function of this class of transporter proteins in 
hematopoietic cell differentiation and to define the underlying mechanisms. 
 
Fig. 3. HSCs main surface markers. HSCs express typical antigens as: CD34, CD117, CD164, 
CD202b, CD31, Flk-1, CD184, CD338 or ABCG2, Notch-1 concomitantly with the lack of 
terminal differentiation markers (CD4 and CD8).   
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2.2 Classification 
According to its hematopoietic repopulation capacity, the hematopoietic stem cell pool can 
be subdivided into three main groups:  
a. short-term HSCs, capable of generating clones of differentiating cells for only 4–6 
weeks;  
b. intermediate-term HSCs, capable of sustaining a differentiating cell progeny for 6–8 
months before becoming extinct; 
c. long-term HSCs, capable of maintaining hematopoiesis indefinitely (Testa, 2011). 
2.3 HSC sources 
HSCs can be harvested from healthy donors either by bone marrow aspiration, peripheral 
stem cell mobilization or from umbilical cord blood (Dick, 2003). HSCs located in the bone 
marrow present an estimated frequency of 0.01% of total nucleated cells and can be collected 
by iliac crest puncture and then separated from the other blood cells by magnetic beads or 
cell sorting.  
Umbilical cord blood (UCB) is a source of the rare but precious primitive HSCs and 
progenitor cells that can reconstitute the hematopoietic system in patients with malignant 
and nonmalignant disorders treated with myeloablative therapy. UCB cells possess an 
enhanced progenitor cell proliferation capacity and self-renewal in vitro. UCB is usually 
discarded and it exists in almost limitless supply. The blood remaining in the delivered 
placenta is safely and easily collected and stored. The predominant collection procedure 
currently involves a relatively simple venipuncture, followed by gravity drainage into a 
standard sterile anti-coagulant-filled blood bag, using a closed system, similar to that 
utilized for whole blood collection (Bojanic & Golubic Cepulic, 2006). 
Peripheral blood hematopoietic stem cells (PBSCs) have numerous advantages in 
comparison with traditionally used bone marrow. PBSCs collection by leukapheresis 
procedure is simple and better tolerated than bone marrow harvest. PBCSs are mobilized by 
myelosupressive chemotherapy or/and hematopoietic growth factors. Leukapheresis 
product contains PBSCs along with committed lineage of progenitors and precursors which 
contribute to faster hematopoietic recovery.  
Unfortunately, the expansion of HSCs in vitro is difficult to achieve because the proliferation is 
accompanied by differentiation. This is presumably caused by a lack of appropriate cues that 
are provided in vivo by the microenvironment. The most excellent defined culture medium for 
HSCs expansion is supplemented with cytokines such as fetal liver tyrosine kinase-3 ligand 
(FLT3-L), stem cell factor (SCF), interleukin-3 (IL-3) and thrombopoietin (TPO). Interestingly, 
mesenchymal stem cells (MSCs), which are characterized by multi-differentiation potential, are 
important players of the bone marrow HSCs niche. In recent years, MSCs have been shown to 
support HSCs maintenance and engraftment (Jing et al., 2010). 
3. Factors involved in hematopoiesis 
Hematopoiesis is a highly coordinated process wherein HSCs differentiate into mature 
blood cells supported by a physical environment called niche (Figure 3). The bone marrow 
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niche is the most important post-natal microenvironment in which HSCs proliferate, mature 
and give rise to myeloid and lymphoid progenitors. BM is present in the medullary cavities 
of all animal bones. Unlike secondary lymphoid organs such as spleen with distinct gross 
structures including red and white pulp, BM has no clear structural features, except for the 
endosteum that contains osteoblasts. The endosteum region comes in contact with calcified 
hard bones and provides a special microenvironment to HSCs, which is necessary for the 
maintenance of HSC activity (Kondo, 2010).  
Within the niche, HSCs are believed to receive support and growth signals originating from 
several sources, including: fibroblasts, endothelial and reticular cells, adipocytes, osteoblasts 
and mesenchymal stem cells. The main function of the niche is to integrate local changes in 
nutrients, oxygen, paracrine and autocrine signals and to change HSCs quiescence, 
trafficking, and/or expansion in response to signals from the systemic circulation (Broner & 
Carson, 2009). Although the nature of true MSCs remains misunderstood, CXC chemokine 
ligand 12 (CXCL12) – expressing CD146 MSCs were recently reported to be self-renewing 
progenitors that reside on the sinusoidal surfaces and contribute to organization of the 
sinusoidal wall structure, produce angiopoietin-1 (Ang-1), and are capable of generating 
osteoblasts that form the endosteal niche (Konopleva & Jordan, 2011).  
These CXCL12 reticular cells may serve as a transit pathway for shuttling HSCs between the 
osteoblastic and vascular niches where essential but different maintenance signals are 
provided. Cytokines and chemokines produced by bone marrow MSCs concentrate in 
particular niches secondary to varying local production and through the effects of cytokine-
binding glycosaminoglycans. Of these, CXCL12/stromal cell–derived factor-1 alpha 
positively regulates HSCs homing, while transforming growth factors FMS-like tyrosine 
kinase 3 (Flt3) ligand and Ang-1 function act as quiescence factors.  
CXCL12-CXCR4 signaling is involved in homing of HSCs into BM during ontogeny as well 
as survival and proliferation of colony-forming progenitor cells. The CXCR4-selective 
antagonist–induced mobilization of HSCs into the peripheral blood further indicates a role 
for CXCL12 in retaining HSCs in hematopoietic organs. BM engraftment involves 
subsequent cell-to-cell interactions through the BMSC-produced complex extracellular 
matrix. Thus, vascular cell adhesion molecule-1 (VCAM-1) or fibronectin is critical for 
adhesion to the BM derived MSCs.   
In this way, the control of hematopoietic stem cell proliferation kinetics is critically 
important for the regulation of correct hematopoietic cells production. These control 
mechanisms could be classified in intrinsic or extrinsic to the stem cells, or a combination of 
both.  
Extrinsic control means that self-renewal and differentiation can be controlled by external 
factors, such as cell–cell interactions in the hematopoietic microenvironment or cytokines as 
SCF (stem cell factor) and its receptor c-kit, Flt-3 ligand, TGF-ǃ, TNF- and others. 
Cytokines regulate a variety of hematopoietic cell functions through the activation of 
multiple signal transduction pathways. The major pathways relevant to cell proliferation 
and differentiation are the Janus kinase (Jak)/signal transducers and activators of 
transcription (STATs), the mitogen-activated protein (MAP) kinase and the 
phosphatidylinositol (PI) 3-kinase pathways. 
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Yet, in intrinsic control, the expression of other transcription factors has been shown to be 
essential for hematopoietic cell development from the earliest stages, as: SCL (stem cell 
leukaemia hematopoietic transcription factor); GATA-2; gene products involved in cell cycle 
control, such as the cyclin dependent kinase inhibitors (CKIs) p16, p21 and p27.   
Notch-1–Jagged pathway may serve to integrate extracellular signals with intracellular 
signalling and cell cycle control. Notch-1 is a surface receptor on hematopoietic stem cell 
membranes that binds to its ligand, Jagged, on stromal cells. This results in cleavage of the 
cytoplasmic portion of Notch-1, which can then act as a transcription factor (Gordon, 2005). 
 
Fig. 4. Schematic representation of main bone marrow niche cells: A- hematopoietic stem 
cells, B- adipocytes, C- mesenchymal stem cells, D- reticular cells, E- osteoclasts, and F- 
osteoblasts.  
4. Leukemia and leukemic development 
Leukemia is the consequence of stepwise genetic alterations that confer both proliferative 
and survival advantage, as well as self-renewal capacity to the malignant cells (Lane et al., 
2011). When the HSCs processes of self-renewal and differentiation become deregulated or 
uncoupled, leukemias can result, characterized by an accumulation of immature blast cells 
that fail to differentiate into functional cells. Two types of abnormal events can lead to 
leukemia. First, a normal stem cell acquires several mutations (from different types of 
genetic events) and, due to epigenetic changes that alter its growth control, the resistance to 
apoptosis is increased, interfering with the ability of its progeny to differentiate. Second, 
partially differentiated cells restore gene expression patterns that allow them to reacquire 
the unique self-renewal properties of stem cells while also interferes with their subsequent 
ability to differentiate (Testa, 2011). 
Hanahan & Weinberg (2000) described the rules that govern the transformation of normal 
cells into a malignant cell. The six main properties that define malignant cells are: self-
sufficiency in growth signals; insensitivity to growth inhibitory signals; evasion of 
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programmed cell death (apoptosis); limitless replicative potential; sustained angiogenesis; 
and tissue invasion and metastasis. 
Oncogenic events
HSCc Progenitor
cell
LSCs
Cancer
 
Fig. 5. Cancer stem cell hypothesis. A normal stem cell acquires several mutations and in 
consequence, by epigenetic changes that alter its growth control, its resistance to apoptosis 
increased and the ability of its progeny to differentiate is changed. Partially differentiated cells 
restore gene expression patterns that allow these cells to reacquire the unique self-renewal 
properties of stem cells while also interfere with their subsequent ability to differentiate.   
The “cancer stem cell hypothesis” has gained considerable interest in recent years. This 
theory states that cells in a tumor are organized as a hierarchy similar to that of normal 
tissues, and are maintained by a small subset of tumor cells that are ultimately responsible 
for tumor formation and growth. These cells, defined as “cancer stem cells” (CSCs) or 
“tumor initiating cells” (TICs), possess several key properties of normal tissue stem cells 
including self-renewal, unlimited proliferative potential (i.e., the ability of a cell to renew 
itself indefinitely in an undifferentiated state), infrequent or slow replication, resistance to 
toxic xenobiotics, high DNA repair capacity, and the ability to give rise to daughter cells that 
differentiate. However, the major difference between cancer growth and normal tissue 
renewal is that whereas normal transit amplifying cells usually differentiate and die, at 
various levels of differentiation, the cancer transit-amplifying cells fail to differentiate 
normally and instead, accumulate (i.e. they undergo maturation arrest), resulting in cancer 
growth (Soltanian & Matin, 2011). 
In the last years, studies have also clearly demonstrated that leukemia populations are 
highly heterogeneous and that the disease is propagated by a subpopulation of leukemia 
stem cells (LSC). LSCs, like normal hematopoietic stem cells, possess a range of biological 
characteristics that enable their long-term survival. Therefore, LSCs reside in a mostly 
quiescent state, and as a consequence, the overall activity of many chemotherapeutic agents 
that function by targeting cycling cells is likely diminished (Konopleva & Jordan, 2011).  
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LSCs infiltrate the bone marrow and interfere with the normal HSC-microenvironment 
homeostasis. Available data indicate that LSCs also interact with the hematopoietic 
microenvironment to maintain self-renewal and to mitigate the effects of cytotoxic 
chemotherapy (Lane et al., 2011) 
4.1 Leukemia stem cells characterization 
The immunophenotype and isolation of LSCs were first described by Lapidot et al.(1994) 
from primary human AML samples and, later, studies have shown that LSCs can be defined 
as expressing CD34, CD382, HLA-DR2, CD902, CD117 and CD123. Some of these markers 
are also detected in HSCs, but the expression of CD123 seems to be leukemic-specific (Blair 
et al., 1998).   
Another LSC specific antigen is C-type lectin-like molecule-1, CLL-1. This antigen was 
demonstrated to be capable of identifying residual leukemic CD34+CD38− cells in clinical 
remission bone marrow samples. However, more recent data indicate that the phenotype of 
LSCs may be somewhat variable from patient to patient and that, in some cases, more than one 
phenotypically distinct subpopulation may possess LSC activity (Konopleva & Jordan, 2011). 
Expression of Oct-4 is another similarity between normal and cancer stem cells. Oct-4, a 
member of the family of POU-domain transcription factors, is expressed in pluripotent 
embryonic stem and germ cells. Oct-4 mRNA is normally found in totipotent and 
pluripotent stem cells of pregastrulation embryos (Soltanian & Matin, 2011).  Expression of 
this factor plays a crucial role in maintaining the self-renewing, cancer stem-cell-like, and 
chemoradioresistant properties in lung cancer-derived CD133+ cells (Chen et al., 2008). 
Oct-4 gene product is expressed in several types of adult pluripotent stem cells including 
kidney, breast, epithelial, pancreatic, mesenchymal, gastric and liver, as well as in tumor cell 
lines derived from pancreas and liver (Tai et al., 2005). According to Marques et al. (2010) it is 
also possible that the resistance phenotype developed by leukemic cells is determined by ABC 
transporter expression which is probably activated by the induction of the Oct-4 transcription 
factor. The ABCB1, ABCG2 and ABCC1 transporters exhibit binding sites (octamer-
ATGCAAAT) for the Oct-4 transcription factor. The presence of these binding sites in the gene 
promoter of these transport proteins suggests that the transporter regulation pathways may be 
initiated at the Oct-4 recognized binding sites. However, the presence of Oct-4 alone is not 
always sufficient for induction of transporter genes. Transporter expression levels are often 
dependent upon Oct-4 interactions with other transcription factors. 
4.2 Genetic pathways of LSCs 
4.2.1 Wnt/Catenin 
The Wnt/Catenin signaling has been implicated in the self-renewal of LSCs. Wnt proteins 
are a large family of glycoproteins that bind to Frizzled receptors and LRP5/6 coreceptors. 
By stabilizing the mediator ǃ-catenin, they start a complex signaling cascade that plays a 
significant role in regulating cell proliferation and differentiation. Wnt cascade has appeared 
as a critical regulator of stem cells self-renewal. Comparing the expression of normal 
hematopoietic stem cells to that of AML leukemic stem cells, evidences show that the Wnt 
signaling pathway is aberrantly regulated in leukemic stem cells.  
www.intechopen.com
 Advances in Hematopoietic Stem Cell Research 
 
270 
 
 
 
 
Fig. 6. LSCs main surface markers. LSCs can be defined as CD34, CD382, HLA-DR2, CD902, 
CD117 and CD123. The expression of CD123 seems to be leukemic-specific. Another LSC 
specific antigen is C-type lectin-like molecule-1, CLL-1. 
4.2.2 PTEN (Akt/mTOR) 
PTEN is a phosphatase that negatively regulates signaling through the PI3K pathway, 
attenuating proliferation and survival signals. PTEN deficiency causes an initial expansion 
of normal hematopoietic stem cells due to their cycling, followed by their exhaustion. In 
contrast to this requirement for PTEN in the maintenance of hematopoietic stem cells, 
leukemic stem cells arise and expand in numbers following PTEN deletion. The observation 
that PTEN deletion had opposite effects on normal hematopoietic stem cells compared to 
leukemic stem cells raised possibility for therapeutic targeting of this pathway to eliminate 
only the leukemic stem cells, without affecting normal hematopoietic stem cells. Since PTEN 
deletion causes increased AKT and mTOR activation, it seems logical that mTOR targeting 
by pharmacological agents, such as rapamycin, could represent an interesting option for 
AML treatment (Testa, 2011). 
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4.2.3 NF-kB 
In addition to genes involved in the control of stem cell self-renewal, leukemic stem cells are 
expected to express, at high levels, genes involved in anti-apoptotic mechanisms. In this context, 
particular attention has been focused on the study of NF-kB. NF-kB plays a critical role in 
inflammation, anti-apoptotic responses, and carcinogenesis. High NF-kB expression was found 
in primitive AML blasts. In particular, the constitutive activation of NF-kB was observed in 
AML cell populations enriched in leukemic stem cells, but not in normal hematopoietic stem 
cells. According to these observations, it seemed clear that NF-kB could be a potential 
therapeutic target for attempting leukemia stem cell eradication (Guzman et al., 2001). 
4.2.4 BMI1  
BMI1 is a polycomb group protein which, together with Ring1 proteins, is part of PRC1 
complex that has histone H2A-K119 ubiquitin E3 ligase activity. BMI1 has a role in HOX 
gene (HOXC13) silencing by H2A ubiquitylation (Cao et al, 2005). BMI1 is also known to be 
important in the regulation and maintenance of proliferative/self-renewal potential in both 
normal hematopoietic and leukemic stem cells (Park et al, 2003). Upon knockdown of BMI-1, 
cells lose their ability to engraft and reconstitute leukemia in mice (Bomken et al., 2010). 
4.3 Xenotransplantation model of leukemia 
A key component for understanding the biological mechanisms for tumor heterogeneity is 
the ability to functionally assess the capacity for limitless proliferative capacity for 
segregated populations of tumor cells. Unfortunately, for hematologic malignancies, in vitro 
culture assays are not entirely effective as a means of functionally assessing self-renewal 
capacity. Thus, transplantation assays in which candidate populations are assessed for their 
ability to establish long-term serial engraftment of recipient animals is the gold standard for 
assigning limitless proliferative capability, i.e. self-renewal. For murine studies, the 
availability of syngeneic transplantation models has been responsible in large part for our in 
depth understanding of the normal murine hematopoietic hierarchy. 
Since the 70 s, there is ample evidence supporting the existence of a discrete compartment of 
slowly cycling leukemic cells that are resistant to standard chemotherapeutic agents. These 
cell populations were felt to represent the leukemic stem cells and though many 
observations were consistent with this hypothesis, there was no direct evidence that this was 
indeed the case. As the first direct evidence for the existence of cancer stem cells, the work of 
Lapidot et al. (1994) represented a milestone in the history of the leukemic stem cell model. 
This study identified an infrequent population of leukemic cells capable of recapitulating 
the human tumor in xenotransplants. A key finding was that the SCID mouse leukemia 
repopulating cell, SRC, possessed a phenotype that was similar to that of the normal 
hematopoietic stem cell (CD34+ and CD38−). 
4.4 Acute myeloid leukemia 
Acute myeloid leukemia (AML) is a clonal disorder characterized by arrest of differentiation 
in the myeloid lineage coupled with an accumulation of immature progenitors in the bone 
marrow, resulting in hematopoietic failure (Pollyea et al., 2011). AML is the most common 
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acute leukemia in adults, affecting roughly three out of 100.000 people. AML patients are 
predominantly elderly, with a median age at diagnosis of 67 (National Cancer Institute 
1975–2007). 
In AML, there is wide patient-to-patient heterogeneity in the appearance of the leukemic 
blasts. Conventionally, AML is classified into seven French–American–British (FAB) 
subtypes corresponding to the maturation stage of the leukemia (Warner et al., 2004). 
The discovery of leukemia-initiating cells in acute myeloid leukemias (AMLs) started with 
the discovery that the large majority of AML blasts do not proliferate and only a small 
minority is capable of forming new colonies (Testa, 2011). 
A common feature to all AML cases is the arrested aberrant differentiation leading to an 
accumulation of more than 20% blast cells in the bone marrow (Gilliland & Tallman, 2002). 
More than 80% of myeloid leukemias are associated with at least one chromosomal 
rearrangement (Pandolfi, 2001), and over 100 different chromosomal translocations have been 
cloned (Gilliland & Tallman, 2002). Frequently, these translocations involve genes encoding 
transcription factors that have been shown to play an important role in hematopoietic lineage 
development. Thus, alteration of the transcriptional machinery appears to be a common 
mechanism leading to arrested differentiation (Pandolfi, 2001; Tenen, 2003). 
Clinical investigation and experimental animal models suggest that at least two genetic 
alterations are required for the clinical manifestation of acute leukemia. According to the model 
proposed by Gilliland & Tallman (2002), cooperation between class I activating mutations and 
class II mutations that induce termination of differentiation give rise to AML. The class I 
mutations, such as mutations in the receptor tyrosine kinase genes FLT3 and KIT, RAS family 
members, and loss of function of neurofibromin 1, confer proliferative and/or survival 
advantage to hematopoietic progenitors, typically as a consequence of aberrant activation of 
signal transduction pathways. The class II mutations lead to a halt in differentiation via 
interference with transcription factors or co-activators (Frankfurt et al., 2009). 
While the LSC appears to share many of the cell surface markers previously identified for 
HSC such as CD34, CD38, HLA-DR, and CD71, there have been several groups who have 
reported surface markers that are differentially expressed in the two populations. CD90 or 
Thy-1 is one marker that has been described to be potentially specific of the LSC 
compartment. Thy-1 is downregulated in normal hematopoiesis as the most primitive stem 
cells progress toward the progenitor stage. This finding of the lack of expression on LSC 
might suggest that the primitive stem cell does not contribute to the primary pathological 
event, or that Thy-1 expression is downregulated as a result of the leukemogenic events 
(Hope et al., 2003). 
The interaction between CXCL12 (stromal cell–derived factor-1 alpha) and its receptor 
CXCR4 on leukemic progenitor cells contributes to their homing to the bone marrow 
microenvironment. CXCR4 levels are significantly elevated in leukemic cells from patients 
with AML and CXCR4 expression is associated with poor outcome (Konopleva & Jordan, 
2011). Constitutive activation of the nuclear factor kappa B (NF-kB) pathway in primary 
human AML stem cells provided evidence that NF-kB plays a significant role in the overall 
survival of LSCs as well as AML cell types in general. This pathway is strongly implicated 
as a central target in developing LSC-specific therapies (Konopleva & Jordan, 2011). 
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FLT3, a member of the class III tyrosine kinase receptor family, is expressed in normal 
hematopoietic progenitors as well as in leukemic blasts, and it plays an important role in cell 
proliferation, differentiation, and survival. Activation of the FLT3 receptor by the FLT3 
ligand leads to receptor dimerization and phosphorylation, and activation of downstream 
signaling pathways, including the Janus kinase (JAK) 2 signal transducer (JAK2), signal 
transducer and activator of transcription (STAT) 5, and mitogen-activated protein kinase 
(MAPK) pathways. Mutations in the FLT3 gene, found in approximately 40% of patients 
with AML, are believed to promote its autophosphorylation and constitutive activation, 
leading to ligand-independent proliferation (Frankfurt et al., 2009). 
The adhesion receptor CD96 (TACTILE) is a transmembrane glycoprotein possessing three 
extracellular immunoglobulin-like domains. It is a member of the Ig gene superfamily and 
was first identified as a gene expressed in activated T cells. CD96 was described as a tumor 
marker AML stem cell (Konopleva & Jordan, 2011). Hosen et al. (2011) showed that AML-
LSC can be distinguished from normal HSC by the presence of CD96 expression. This 
finding suggests that CD96 also may prove to be an excellent target for antibody therapy 
against LSC because hematopoietic progenitors are regenerated rapidly from HSC. 
Another adhesion molecule, CD44, has been demonstrated to be a key regulator of AML 
LSCs homing to microenvironmental niches, maintaining a primitive state. CD44 mediates 
adhesive cell-cell and cell–complex extracellular matrix interactions through binding to its 
main ligand, hyaluronan, a glycosaminoglycan highly concentrated in the endosteal region. 
Other ligands include osteopontin, fibronectin, and selectin, all of which are involved in cell 
trafficking and lodgment. Beyond its adhesion function, CD44 can also transduce multiple 
intracellular signal transduction pathways when bound to hyaluronan or to specific 
function-activating monoclonal antibodies (Konopleva & Jordan, 2011). 
5. Conclusions 
Adult hematopoietic stem cells are undifferentiated cells capable of self-renewal and 
differentiation potential in several cell types that comprise the hematopoietic tissue. These 
cells have been used in bone marrow transplantation for treatment of hematological 
malignancies as well as non-hematological diseases. The HSC is the main component in the 
process of hematopoiesis which, together with the cells that make up the bone marrow 
stromal environment and other intrinsic and extrinsic factors, orchestrates the entire 
production of progenitors and terminally differentiated blood cells. 
However, when this process of cell production is unbalanced, leading to an exacerbated and 
uncontrolled proliferation of blood progenitor cells, leukemia may develop.The ultimate 
challenge in coming years will be to understand the stem cell  ‘programme’, particularly the 
control of self-renewal, in an attempt to develop novel, stem cell-directed therapies. An 
improved understanding of clonal evolution will be critical if we are to ensure that cancers 
are not able to evolve mechanisms to evade the new directed therapies. However, reducing 
the risk of relapse and minimizing long-term side effects should always remain the ultimate 
goal of understanding the CSCs. 
With little doubt, the leukemia stem cell model has had the greatest clinical impact on our 
understanding and treatment of Philadelphia chromosome positive leukemias. Effective 
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targeted agents and the ability to follow the impact of therapy on critical rare sub-
populations of the malignant clone has greatly advanced our understanding of chronic 
myeloid leukemia. 
For AML, the clinical impact of the leukemic stem cell model is less clear. The ability to 
isolate and characterize rare LSC populations has had a significant importance on our 
understanding of the biology of AML. In the past decade, we have gained considerable 
insight into the properties that distinguish leukemic stem cells from their normal 
counterparts and some of the rules that govern the leukemic hierarchy. 
Despite the wide variance in techniques and to some degree expression profiles, common 
signaling pathways have been shown to play a role not only in AML stem cells, but also in 
cancer stem cells in general. These include BMI1, Wnt, Sonic Hedgehog, Notch, and NF-kB. 
These pathways are being evaluated for their role in LSC biology and agents targeting these 
pathways are making their way through the pre-clinical focus. 
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